Senti Biosciences (SNTI) announced that its stockholders have approved all key proposals at its 2026 Annual Meeting on October 15, 2026, most notably the approval of a previously announced merger agreement and a reverse stock split.
Key Details
- Merger Agreement Approved: Shareholders approved the Agreement and Plan of Merger dated July 14, 2026, with ST NewCo Limited. The proposal passed with both the required majority of outstanding shares and a "majority of the minority" vote.
- Reverse Stock Split Authorized: The company received approval to amend its Certificate of Incorporation for a reverse stock split of its common stock at a ratio between 1-for-20 and 1-for-50, with the final ratio to be determined by the Board of Directors.
- Other Key Approvals: Stockholders also elected three Class I directors and approved the potential issuance of more than 19.99% of outstanding common stock upon the exchange of Senior Secured Convertible Notes.